AstraZeneca has received $ 486 million to develop an antibody treatment similar to that received by US President Donald Trump and wants to deliver up to 100,000 doses by the end of 2020. The US government could buy up to one million additional doses in 2021.

The agreement between the company and the US government involves the development of a cocktail of monoclonal antibodies. Antibody products have been in the spotlight since Trump received antibody treatment.

Image upload

Similar Articles

Similar Bookmarks

Connected Bookmarks